Jasso-Baltazar Erick Augusto, Solís-Galindo Francisco Alfonso, Muñoz-Hernández Melisa Alejandra, Quintal-Medina Ismael Antonio
Instituto Mexicano del Seguro Social, Hospital de Especialidades No. 71, Servicio de Medicina Interna. Torreón, Coahuila, México.
Instituto Mexicano del Seguro Social, Hospital de Especialidades No. 71, Servicio de Gastroenterología. Torreón, Coahuila, México.
Rev Med Inst Mex Seguro Soc. 2022 May 2;60(3):283-288.
Patients with chronic kidney disease (CKD) have a higher prevalence of hepatitis C virus (HCV) infection compared to the general population, and they also present higher morbidity and mortality if they are not treated. Current treatment is based on different direct-acting antiviral (DAA) schemes, which are available in the Mexican health system. However, the efficacy and safety of DAA treatment in patients with CKD on hemodialysis and HCV infection are unknown in Mexican population.
To determine the efficacy through sustained viral response (SVR) and the safety of DAAs in patients with CKD on hemodialysis and chronic HCV infection in the Mexican population.
Real-life cohort study. Patients with CKD on hemodialysis and HCV infection treated with DAAs from a third level hospital were included. Descriptive statistics of the clinical characteristics were performed, efficacy was determined by SVR and safety with the global frequency of adverse effects associated with treatment.
25 patients were included. All of them received treatment with glecaprebir/pibrentasvir for 8 weeks. The mean age was 57.8 years and the median time of CKD on hemodialysis was 5 years. 96% of patients had HCV genotype 1B. 100% of the patients presented SVR and the most frequent adverse effects were headache, nausea and fatigue.
In the Mexican population studied, patients with HCV and CKD on hemodialysis presented a sustained viral response of 100% with glecaprevir/pibrentasvir with mild adverse effects.
与普通人群相比，慢性肾脏病（CKD）患者丙型肝炎病毒（HCV）感染的患病率更高，并且若不接受治疗，他们的发病率和死亡率也更高。目前的治疗基于不同的直接抗病毒（DAA）方案，这些方案在墨西哥卫生系统中可用。然而，在墨西哥人群中，DAA治疗对接受血液透析的CKD患者和HCV感染患者的疗效和安全性尚不清楚。
确定在墨西哥人群中，接受血液透析的CKD患者和慢性HCV感染患者使用DAA的持续病毒学应答（SVR）疗效和安全性。
真实队列研究。纳入一家三级医院接受DAA治疗的血液透析CKD患者和HCV感染患者。对临床特征进行描述性统计，通过SVR确定疗效，并通过与治疗相关的不良反应总体发生率确定安全性。
纳入25例患者。他们均接受格卡瑞韦/哌仑他韦治疗8周。平均年龄为57.8岁，血液透析CKD的中位时间为5年。96%的患者为HCV 1B基因型。100%的患者出现SVR，最常见的不良反应为头痛、恶心和疲劳。
在本研究的墨西哥人群中，血液透析的HCV和CKD患者使用格卡瑞韦/哌仑他韦的持续病毒学应答率为100%，且不良反应轻微。
